SCHEMBL714335

SCHEMBL714335

Cc1nc(N)nc(N[C@@H](C)c2cc3cccc(C)c3nc2N2CCN(CC(=O)N3CCOCC3)CC2)n1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 11/20 0.42
ALDH1A1 P00352 3/20 0.41
MEN1 O00255 2/20 0.41
NPC1 O15118 1/20 0.41
NR1I2 O75469 1/20 0.41
USP2 O75604 1/20 0.41
TP53 P04637 1/20 0.41
GAA P10253 1/20 0.41
MAPT P10636 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
RAB9A P51151 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
LMNA P02545 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
TSHR P16473 1/20 0.37
KDM4E B2RXH2 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714336 1.00 PIK3CD (0.42) PIK3CDALDH1A1MEN1NPC1NR1I2
SCHEMBL715520 0.87 PIK3CD (0.46) PIK3CDALDH1A1MEN1NPC1NR1I2
SCHEMBL713709 0.86 PIK3CD (0.53) PIK3CD
SCHEMBL713708 0.86 PIK3CD (0.53) PIK3CD
SCHEMBL716547 0.85 TDP1 (0.44) PIK3CDALDH1A1MEN1NPC1NR1I2
SCHEMBL15875859 0.84 ALDH1A1 (0.44) PIK3CDALDH1A1MEN1NPC1NR1I2
SCHEMBL15875862 0.84 ALDH1A1 (0.44) PIK3CDALDH1A1MEN1NPC1NR1I2
SCHEMBL716189 0.81 TSHR (0.47) PIK3CDALDH1A1USP2GAAMAPT
SCHEMBL715848 0.80 PIK3R2 (0.40) PIK3CDALDH1A1SMN1; SMN2
SCHEMBL718468 0.80 PIK3R2 (0.40) PIK3CDALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP claimed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US claimed
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 PIK3CD 12/4885ALDH1A1 3504/4885MEN1 3000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.